| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
| ln Vitro |
The CID 2745687 (CID2745687) Ki for ERK1/2 phosphorylation using 1 μM Pamoic acid as the agonist is 18 nM[1]. In β-arrestin-2 interaction experiments, CID 2745687 (CID-2745687) is a strong antagonist limited to human GPR35 [2]. With an agonist concentration of 20 μM Zaprinast and the BRET-based GPR35-β-arrestin-2 interaction test, CID 2745687 exhibited moderate potency and concentration dependence at human GPR35, with a pIC50 of 6.70±0.09[2]. CID 2745687 (pIC50=6.27±0.08) completely counteracts Cromolyn disodium's agonistic effects [2].
|
|---|---|
| ln Vivo |
A particular GPR35 antagonist, CID 2745687 (CID2745687; 1 mg/kg; taken orally daily for the last 4 weeks), counteracts the anti-fibrotic effects of lodoxamide[3].
|
| Animal Protocol |
Animal/Disease Models: Sixweeks old male C57BL/6 mice[3]
Doses: 1 mg/kg Route of Administration: Oral administration, every day for 4 weeks Experimental Results: Inhibited Lodoxamide-mediated protective effects. |
| References |
[1]. Pingwei Zhao, et al. Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol. 2010 Oct;78(4):560-8.
[2]. Laura Jenkins, et al. Antagonists of GPR35 display high species ortholog selectivity and varying modes of action. J Pharmacol Exp Ther. 2012 Dec;343(3):683-95. [3]. Mi-Jeong Kim, et al. Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35. Biomol Ther (Seoul). 2019 Jun 13;28(1):92-97. |
| Molecular Formula |
C17H19F2N5O2S
|
|---|---|
| Molecular Weight |
395.43
|
| CAS # |
264233-05-8
|
| SMILES |
CC(C)(NC(N/N=C/C1=C(C(OC)=O)C=NN1C2=C(F)C=C(F)C=C2)=S)C
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 125 mg/mL (316.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5289 mL | 12.6445 mL | 25.2889 mL | |
| 5 mM | 0.5058 mL | 2.5289 mL | 5.0578 mL | |
| 10 mM | 0.2529 mL | 1.2644 mL | 2.5289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
